Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2022 16:30 ET | Source: IntelGenx Technologies Corp.

IntelGenx to Report Third Quarter 2022 Financial Results on November 10, 2022 – Conference Call to Follow

SAINT LAURENT, Quebec, Nov. 03, 2022 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its...
November 02, 2022 08:00 ET | Source: IntelGenx Technologies Corp.

IntelGenx Files Provisional U.S. Patent Application for Advanced Oral Film Formulation Improving Cannabinoid Onset of Action

SAINT LAURENT, Quebec, Nov. 02, 2022 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx”), a leader in pharmaceutical films, today announced it has filed a new...
October 25, 2022 08:00 ET | Source: IntelGenx Technologies Corp.

IntelGenx Receives FDA GDUFA Date for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film

SAINT LAURENT, Quebec, Oct. 25, 2022 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that its previously undisclosed development candidate,...
October 20, 2022 08:30 ET | Source: IntelGenx Technologies Corp.

IntelGenx Announces Issuance of New U.S. Patent Covering VersaFilm® Technology

SAINT LAURENT, Quebec, Oct. 20, 2022 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that the United...
October 18, 2022 08:00 ET | Source: IntelGenx Technologies Corp.

IntelGenx Submits Response to CRL from FDA for RIZAPORT® VersaFilm®

SAINT LAURENT, Quebec, Oct. 18, 2022 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that it has...
October 13, 2022 09:21 ET | Source: IntelGenx Technologies Corp.

IntelGenx’s Collaboration with atai Life Sciences Culminates in the Initiation of First-in-Human Clinical Study of an Oral Thin Film Psychedelic Drug Candidate

SAINT LAURENT, Quebec, Oct. 13, 2022 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today provided an update on its collaboration with its strategic...
September 08, 2022 08:00 ET | Source: IntelGenx Technologies Corp.

IntelGenx Announces Enrollment Reaches Halfway Mark in ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

SAINT LAURENT, Quebec, Sept. 08, 2022 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that patient enrollment in the ongoing Montelukast...
August 11, 2022 16:05 ET | Source: IntelGenx Technologies Corp.

IntelGenx Reports Second Quarter 2022 Financial Results

SAINT LAURENT, Quebec, Aug. 11, 2022 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the second quarter...
August 04, 2022 08:30 ET | Source: IntelGenx Technologies Corp.

IntelGenx to Report Second Quarter 2022 Financial Results on August 11, 2022 – Conference Call to Follow

SAINT LAURENT, Quebec, Aug. 04, 2022 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its...
July 05, 2022 14:00 ET | Source: IntelGenx Technologies Corp.

IntelGenx Announces Completion of Share Issuance in Payment of Principal and Interest on Debentures

SAINT LAURENT, Quebec, July 05, 2022 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) announces that, as previously disclosed on June 1, 2022...